STAAR Surgical Publishes Presentation Highlighting Compelling, Certain Cash Value Offered by Alcon Merger and Meaningful Downside Risks if Alcon Merger is not Approved
ALCLAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today published a presentation reviewing the compelling, certain, premium cash value offered by the Company’s pending merger with Alcon (SIX/NYSE: ALC) and the meaningful downside risks for STAAR stockholders if the Alcon merger is not approved. The presentation is available at investors.staar.com and
Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS
ALC(NYSE:ALC) GENEVA--(BUSINESS WIRE)--Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS
Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS
ALC(NYSE:ALC) GENEVA--(BUSINESS WIRE)--Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS
Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
ALC(NYSE:ALC) GENEVA--(BUSINESS WIRE)--Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
ALC(NYSE:ALC) GENEVA--(BUSINESS WIRE)--Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
Total voting rights and Capital
ALC(NYSE:ALC) Albion Crown VCT PLC
Alcon to Present at 2025 Baird Global Healthcare Conference
ALCGENEVA--(BUSINESS WIRE)--Alcon to Present at 2025 Baird Global Healthcare Conference
Alcon to Present at 2025 Baird Global Healthcare Conference
ALCGENEVA--(BUSINESS WIRE)--Alcon to Present at 2025 Baird Global Healthcare Conference
Alcon Agrees to Acquire STAAR Surgical
ALCGENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Alcon Agrees to Acquire STAAR Surgical
Alcon Agrees to Acquire STAAR Surgical
ALCGENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Alcon Agrees to Acquire STAAR Surgical
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
ALCFDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.
Alcon Receives FDA Approval For TRYPTYR 0.003% For The Treatment Of The Signs And Symptoms Of Dry Eye Disease
ALCNeedham Reiterates Buy on Alcon, Maintains $110 Price Target
ALCAlcon Lowers FY2025 Adj EPS Guidance from $3.15-$3.25 to $3.05-$3.15 vs $3.20 Est; Raises FY2025 Sales Guidance from $10.20B-$10.40B to $10.40B-$10.50B vs $10.42B Est
ALCAlcon Q1 Adj. EPS $0.73 Misses $0.75 Estimate, Sales $2.45B Miss $2.51B Estimate
ALCAlcon Earnings Preview
ALCAlcon Proposes CHF 0.28 Cash Dividend Ahead Of 2025 AGM And Nomination Of New Tech-Focused Board Member
ALCKeybanc Maintains Overweight on Alcon, Raises Price Target to $112
ALCMizuho Maintains Outperform on Alcon, Raises Price Target to $120
ALCNeedham Maintains Buy on Alcon, Raises Price Target to $110
ALCAlcon Acquires Majority Interest in Aurion Biotech; Financial Terms Not Disclosed
ALCAlcon Secures CE Mark For Clareon Vivity IOL, Bringing Next-Generation Presbyopia Correction To Europe
ALCAlcon Eyes Surgical Edge With LENSAR Buyout: Details
ALCAlcon is set to acquire LENSAR Inc. in a $356 million deal. This acquisition includes LENSAR's advanced cataract laser technologies, boosting Alcon's offerings in femtosecond laser-assisted cataract surgery.
Alcon To Acquire LENSAR For $14/Share
ALCNeedham Reiterates Buy on Alcon, Maintains $107 Price Target
ALCBaird Maintains Outperform on Alcon, Raises Price Target to $108
ALCNeedham Maintains Buy on Alcon, Raises Price Target to $107
ALCNeedham Reiterates Buy on Alcon, Maintains $106 Price Target
ALCAlcon Sees FY25 EPS $3.15-$3.25 Vs $3.36 Est.; Revenue $10.2B-$10.4B Vs $10.461B Est.
ALCAlcon Q4 2024 Adj. EPS $0.72 Beats $0.71 Estimate, Sales $2.477B Beat $2.466B Estimate
ALCNeedham Maintains Buy on Alcon, Lowers Price Target to $103
ALC